All sponsors

Takeda $TAK

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS67
PHASE 3 / 2-344
RECRUITING43
READOUTS ≤12 MONTHS17
READOUT SLIPPED >6 MO38%

Delay Index: of 50 active trials registered more than a year ago, 19 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open Takeda on the live radar map → 📅 $TAK readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Brentuximab vedotin
NCT02979522
P1/2Active, not recruitingHodgkin Disease592020-05-05 (+3 mo)
Ponatinib
NCT03589326
P3Active, not recruitingPhiladelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)2452022-08-12 (+25 mo)
TAK-007
NCT05020015
P2Active, not recruitingRelapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)272024-06-16 (-64 mo)
TAK-853
NCT06390995
P1/2Active, not recruitingOvarian Cancer; Solid Tumors282025-04-16 (-5 mo)
Brentuximab Vedotin
NCT05673785
P2Active, not recruitingLymphoma522025-04-27 (-3 mo)
Vedolizumab
NCT04738942
P3Active, not recruitingUlcerative Colitis; Crohn's Disease562025-05-30 (+8 mo)
Tetravalent Dengue Vaccine (TDV)
NCT07047521
P3Active, not recruitingDengue Fever4962026-06-29 (-2 mo)
TAK-279
NCT06254950
P2Active, not recruitingUlcerative Colitis2132026-07-14 (-3 mo)
TAK-360
NCT06812078
P2RecruitingIdiopathic Hypersomnia962026-11-30 (+9 mo)
TAK-360
NCT06952699
P2RecruitingNarcolepsy Type 2882026-11-30 (+8 mo)
TAK-861
NCT07363720
P3Active, not recruitingNarcolepsy Type 1 (NT1); Narcolepsy With Cataplexy982026-12-17
Maribavir
NCT05319353
P3RecruitingCytomegalovirus (CMV)802027-01-18
Zasocitinib (Dose A)
NCT07244263
P2Active, not recruitingHidradenitis Suppurativa912027-02-05
Teduglutide
NCT06973304
P3Active, not recruitingShort Bowel Syndrome132027-02-10
TAK-279
NCT06233461
P2RecruitingCrohn's Disease2682027-02-17 (+5 mo)
TAK-755
NCT04683003
P3Active, not recruitingThrombotic Thrombocytopenic Purpura (TTP)772027-03-16 (+7 mo)
Zasocitinib
NCT07108283
P2Active, not recruitingNonsegmental Vitiligo2072027-03-26 (-7 mo)
TDV
NCT06579755
P3Active, not recruitingDengue Fever8002027-04-14 (+13 mo)
Zasocitinib
NCT06671496
P3Active, not recruitingPsoriatic Arthritis6012027-05-18
Zasocitinib
NCT06671483
P3Active, not recruitingPsoriatic Arthritis15832027-05-18
Zasocitinib
NCT07752108
P3Not yet recruitingPalmoplantar Psoriasis402027-05-30
VICTRIVA
NCT06227910
P3RecruitingCrohn's Disease3962027-06-08
Vedolizumab IV
NCT04779320
P3RecruitingCrohn's Disease (CD)1202027-09-13 (+33 mo)
Vedolizumab IV
NCT03221036
P3Active, not recruitingModerately to Severely Active Ulcerative Colitis3922027-09-24 (+83 mo)
Rusfertide
NCT07648030
P2RecruitingPolycythemia Vera92027-10-28
VONVENDI
NCT07129343
P3RecruitingVon Willebrand Disease (VWD)202027-11-25
TAK-360
NCT07633301
P2RecruitingNarcolepsy Type 1922027-11-28
CASCA
NCT06798012
P2RecruitingChronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)362027-12-02
TAK-755
NCT07392450
P2RecruitingAcute Ischemic Stroke2222027-12-06
TAK-861
NCT05816382
P2/3RecruitingNarcolepsy Type 15002028-02-28 (+14 mo)
Elritercept
NCT05037760
P2RecruitingMyelofibrosis1352028-02-28 (+41 mo)
Mezagitamab
NCT06722235
P3RecruitingImmune Thrombocytopenic Purpura (ITP)1712028-03-16 (+2 mo)
Zasocitinib
NCT07403968
P2RecruitingCrohn's Disease202028-03-30
TAK-881
NCT06076642
P3Active, not recruitingPrimary Immunodeficiency Diseases (PID)532028-05-16 (+12 mo)
Vedolizumab IV
NCT06100289
P3RecruitingUlcerative Colitis; Crohn's Disease702028-05-16 (+11 mo)
TAK-881
NCT06747351
P3RecruitingChronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)592028-06-25
TAK-226
NCT07319845
P2RecruitingMyelodysplastic Syndromes422028-06-26
Rusfertide
NCT07765602
P2Not yet recruitingPolycythemia Vera242028-07-01
Fazirsiran Injection
NCT06165341
P3RecruitingAlpha1-Antitrypsin Deficiency502028-08-26
TAK-330
NCT05156983
P3RecruitingCoagulation Disorder4402028-08-30 (+62 mo)
Mezagitamab
NCT06963827
P3RecruitingKidney Disease3472028-09-07
IGI, 10%
NCT06980480
P3RecruitingMultiple Myeloma; Secondary Immunodeficiency1832028-09-11
Elritercept
NCT06499285
P3RecruitingMyelodysplastic Syndromes2252028-09-15 (-42 mo)
MarsLight-11
NCT07217301
P3RecruitingIO Resistant Squamous and Nonsquamous NSCLC12002028-11-01
TAK-188
NCT07205718
P1/2RecruitingAdvanced or Metastatic Solid Tumors2732028-12-26
Idursulfase-IT
NCT06031259
P2/3Active, not recruitingHunter Syndrome62029-01-01 (-60 mo)
Mezagitamab
NCT07613359
P2RecruitingAntibody-Mediated Rejection (AMR)362029-01-15
Fazirsiran Injection
NCT05677971
P3RecruitingAlpha1-Antitrypsin Deficiency1602029-01-17 (+35 mo)
ELRiSE MDS
NCT07422480
P3RecruitingMyelodysplastic Syndrome; Anemia3002029-04-30
Mezagitamab
NCT06948318
P3RecruitingImmune Thrombocytopenic Purpura (ITP)1502029-07-29
TAK-279
NCT06550076
P3Active, not recruitingPlaque Psoriasis20992029-08-05 (+39 mo)
Vortioxetine tablets
NCT07204314
P3RecruitingMajor Depressive Disorder1802029-09-30
Elritercept
NCT04419649
P2RecruitingMyelodysplastic Syndromes; Cytopenia2102029-10-30 (+93 mo)
ELRISE MF
NCT07623161
P3RecruitingMyelofibrosis; Anemia3242029-12-07
Zasocitinib
NCT07286058
P3RecruitingPsoriatic Arthritis11822029-12-18
Zasocitinib
NCT06764615
P2RecruitingCrohn's Disease; Ulcerative Colitis1922029-12-30
Vedolizumab
NCT06443502
P3RecruitingPouchitis302030-01-31 (+1 mo)
TDV
NCT06665035
P3RecruitingDengue Fever2122030-03-03
Vedolizumab IV
NCT05837897
P3RecruitingCrohn's Disease4082030-03-08
Vonicog Alfa
NCT05582993
P3RecruitingVon Willebrand Disease (VWD)242030-04-11 (+51 mo)
Zasocitinib
NCT07871721
P3Not yet recruitingPsoriatic Arthritis6442030-04-18
Vedolizumab SC
NCT06405087
P3RecruitingUlcerative Colitis; Crohn's Disease702030-08-12 (-17 mo)
TAK-505
NCT07436728
P1/2RecruitingMalignant Solid Tumors1512030-08-18
TAK-360
NCT07646678
P2/3RecruitingIdiopathic Hypersomnia; Narcolepsy Type 15002031-06-15
Vedolizumab IV
NCT05442567
P3RecruitingUlcerative Colitis; Crohn's Disease2402033-02-07 (+36 mo)
Fazirsiran Injection
NCT05899673
P3Active, not recruitingAlpha1-Antitrypsin Deficiency2002033-05-02 (+83 mo)
Zasocitinib
NCT07250802
P3RecruitingPlaque Psoriasis2102034-07-03